Suppr超能文献

黏着斑激酶(FAK)和p21激活激酶1(PAK1)对Stat5在致癌性FLT3和KIT驱动的白血病发生中的调控作用

Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.

作者信息

Chatterjee Anindya, Ghosh Joydeep, Ramdas Baskar, Mali Raghuveer Singh, Martin Holly, Kobayashi Michihiro, Vemula Sasidhar, Canela Victor H, Waskow Emily R, Visconte Valeria, Tiu Ramon V, Smith Catherine C, Shah Neil, Bunting Kevin D, Boswell H Scott, Liu Yan, Chan Rebecca J, Kapur Reuben

机构信息

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

出版信息

Cell Rep. 2014 Nov 20;9(4):1333-48. doi: 10.1016/j.celrep.2014.10.039. Epub 2014 Nov 13.

Abstract

Oncogenic mutations of FLT3 and KIT receptors are associated with poor survival in patients with acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPNs), and currently available drugs are largely ineffective. Although Stat5 has been implicated in regulating several myeloid and lymphoid malignancies, how precisely Stat5 regulates leukemogenesis, including its nuclear translocation to induce gene transcription, is poorly understood. In leukemic cells, we show constitutive activation of focal adhesion kinase (FAK) whose inhibition represses leukemogenesis. Downstream of FAK, activation of Rac1 is regulated by RacGEF Tiam1, whose inhibition prolongs the survival of leukemic mice. Inhibition of the Rac1 effector PAK1 prolongs the survival of leukemic mice in part by inhibiting the nuclear translocation of Stat5. These results reveal a leukemic pathway involving FAK/Tiam1/Rac1/PAK1 and demonstrate an essential role for these signaling molecules in regulating the nuclear translocation of Stat5 in leukemogenesis.

摘要

FLT3和KIT受体的致癌性突变与急性髓系白血病(AML)和骨髓增殖性肿瘤(MPN)患者的不良生存相关,并且目前可用的药物大多无效。尽管Stat5已被认为参与调节多种髓系和淋巴系恶性肿瘤,但Stat5如何精确调节白血病发生,包括其核转位以诱导基因转录,仍知之甚少。在白血病细胞中,我们发现粘着斑激酶(FAK)的组成性激活,其抑制可抑制白血病发生。在FAK的下游,Rac1的激活由RacGEF Tiam1调节,其抑制可延长白血病小鼠的生存期。抑制Rac1效应器PAK1部分通过抑制Stat5的核转位来延长白血病小鼠的生存期。这些结果揭示了一条涉及FAK/Tiam1/Rac1/PAK1的白血病通路,并证明了这些信号分子在调节白血病发生中Stat5的核转位方面的重要作用。

相似文献

1
Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
Cell Rep. 2014 Nov 20;9(4):1333-48. doi: 10.1016/j.celrep.2014.10.039. Epub 2014 Nov 13.
2
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
Sci Transl Med. 2015 Jun 10;7(291):291ra96. doi: 10.1126/scitranslmed.aaa5731.
4
FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Oncotarget. 2016 Mar 1;7(9):9964-74. doi: 10.18632/oncotarget.7128.
7
Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.
J Clin Invest. 2013 Oct;123(10):4449-63. doi: 10.1172/JCI67509. Epub 2013 Sep 16.
9
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.

引用本文的文献

1
Phosphoproteomics identifies determinants of PAK inhibitor sensitivity in leukaemia cells.
Cell Commun Signal. 2025 Mar 13;23(1):135. doi: 10.1186/s12964-025-02107-0.
2
Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.
Pathophysiology. 2023 Aug 1;30(3):296-313. doi: 10.3390/pathophysiology30030024.
5
RHOA Therapeutic Targeting in Hematological Cancers.
Cells. 2023 Jan 28;12(3):433. doi: 10.3390/cells12030433.
7
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma.
EMBO Mol Med. 2022 Dec 7;14(12):e15200. doi: 10.15252/emmm.202115200. Epub 2022 Nov 7.
8
Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.
Leukemia. 2022 Apr;36(4):970-982. doi: 10.1038/s41375-021-01490-0. Epub 2021 Dec 13.
10
p21-Activated kinases as promising therapeutic targets in hematological malignancies.
Leukemia. 2022 Feb;36(2):315-326. doi: 10.1038/s41375-021-01451-7. Epub 2021 Oct 25.

本文引用的文献

1
Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.
J Clin Invest. 2013 Oct;123(10):4449-63. doi: 10.1172/JCI67509. Epub 2013 Sep 16.
2
PAK signaling in cancer.
Cell Logist. 2012 Apr 1;2(2):105-116. doi: 10.4161/cl.21882.
3
5
Rac1 signalling modulates a STAT5/BCL-6 transcriptional switch on cell-cycle-associated target gene promoters.
Nucleic Acids Res. 2012 Sep;40(16):7776-87. doi: 10.1093/nar/gks571. Epub 2012 Jun 20.
6
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016.
7
Fak depletion in both hematopoietic and nonhematopoietic niche cells leads to hematopoietic stem cell expansion.
Exp Hematol. 2012 Apr;40(4):307-17.e3. doi: 10.1016/j.exphem.2011.11.010. Epub 2011 Dec 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验